

Technology Advisory Committee A Interests Register

Upadacitinib for previously treated moderately to severely active Crohn's disease [ID4027]

Publication Date: 21/06/2023

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
Dominic Pivonka	TAC A Committee Member	Financial Interests - Conflicted	Dominic Pivonka's employer (AbbVie) is the company sponsor and a possible comparator company	23/03/2023	N/A	It was agreed that Dominic's declaration would prevent him from participating in discussions on this evaluation.
Becky Pennington	TAC A Committee Member	Financial Interest	Becky Pennington has undertaken consultancy work for Takeda and received payment. The work was methodological research about including informal carers and did not relate to Crohn's disease or vedolizumab.	20/03/2023	N/A	It was agreed that Becky's declaration would not prevent her from participating in discussions on this evaluation.
Fiona MacPherson Smith	TAC A Committee Member	Non-Financial Personal Interest	Crohn's disease – Fiona's husband is currently receiving a monoclonal antibody through the NHS for treatment of this condition.	20/03/2023	N/A	It was agreed that Fiona's declaration would not prevent her from participating in

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
						discussions on this evaluation.
Emtiyaz Chowdhury	TAC A Committee Member	Non-Financial Professional Interest	Emtiyaz works for Parexel which is a CRO offering services to the Pharma industry. The manufacturer is one of Parexel's clients however she has had no direct involvement with the technology under discussion.	28/03/2023	N/A	It was agreed that Emtiyaz's declaration would not prevent her from participating in discussions on this evaluation.
Dr Peter Irving	Clinical expert	Direct financial interests	<p>Dr Peter Irving in the last 12 months has received honoraria from the following companies for the listed activities.</p> <ul style="list-style-type: none"> •Lecture fees: •AbbVie, BMS, Galapagos, Gilead, Janssen, Lilly, Pfizer, Takeda, •Advisory fees: •AbbVie, BMS, Gilead, Janssen, Lilly, Pfizer, Takeda 	04/04/2023	N/A	It was agreed that Peter's declaration would not prevent him from participating in discussions on this evaluation.

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Interest ceased	Comments
			<p>He has also received grants for investigator-initiated research from the following companies in the last 12 months:</p> <ul style="list-style-type: none"> • Financial support for research: • Celltrion, Pfizer, Takeda, Galapagos 			

GUIDANCE NOTES FOR COMPLETION OF THE INTERESTS REGISTER

Relevant dates: Detail here the date the interest was declared, and when it ceased - if applicable. For example, if an individual has ceased to hold shares or undertake relevant private practice.